Asia Pacific Embolization Devices Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The Asia Pacific embolization devices market is projected to grow significantly, reaching approximately US$ 1,302.34 million by 2031, up from US$ 659.10 million in 2024, with an estimated compound annual growth rate (CAGR) of 10.3% from 2025 to 2031.

Executive Summary and Market Analysis

The market is divided into several regions, including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. A key driver of this market growth is the rising incidence of cancer and other medical conditions, which increases the demand for interventional procedures like embolization. Additionally, advancements in technology have significantly improved the efficacy and safety of embolization devices, including innovations such as drug-eluting beads, microcatheters, and new coil designs. These improvements not only enhance clinical outcomes but also minimize procedure times and reduce post-operative complications, making these procedures more appealing to both healthcare providers and patients.

The trend towards minimally invasive surgical techniques is another crucial factor contributing to market growth. Such procedures offer numerous advantages, including shorter hospital stays, faster recovery, and a lower risk of complications compared to traditional surgeries. As awareness of these benefits grows among healthcare providers and patients, the demand for embolization procedures is expected to increase.

Market Segmentation Analysis

The Asia Pacific embolization devices market can be segmented by type, application, and end user.

By Type: The market includes embolization coils, plugs, beads, glues, and others. In 2024, embolization coils held the largest market share, further divided into central and peripheral applications.
By Application: The market is categorized into neurology, peripheral vascular disease, oncology, urology, and others, with neurology being the leading segment in 2024.
By End User: The end users are primarily hospitals, ambulatory centers, and others, with hospitals dominating the market share in 2024.

Market Outlook

Embolization is a minimally invasive technique that blocks blood flow to specific areas, such as tumors or abnormal blood vessels, using embolic agents delivered via catheters. This method is widely used for treating arteriovenous malformations (AVMs), aneurysms, and certain cancers. The preference for these techniques is increasing due to their advantages over traditional surgical methods, including reduced hospital stays, lower complication rates, and quicker recovery times.

For instance, uterine artery embolization is an effective alternative to hysterectomy for treating uterine fibroids, achieving success rates exceeding 90% while preserving uterine function, which is particularly important for women of reproductive age. Furthermore, older patients with comorbidities often prefer minimally invasive options. Transarterial chemoembolization (TACE) has become a standard first-line treatment for hepatocellular carcinoma (HCC), a prevalent liver cancer among older adults. The use of microspheres and drug-eluting beads in TACE not only blocks blood supply but also delivers localized chemotherapy, enhancing treatment efficacy and minimizing systemic side effects. According to the National Cancer Institute, TACE can extend median survival for intermediate-stage HCC patients to 20 months, providing a safer alternative to surgical resection.

The emergence of bioresorbable embolic materials is another significant development in the market, offering temporary occlusion that the body gradually absorbs, thus reducing long-term complications and allowing for future treatment options. As healthcare systems increasingly favor minimally invasive and cost-effective interventions, both patients and clinicians are prioritizing treatment options that minimize trauma, recovery time, and complications. Consequently, embolization is becoming a preferred alternative to traditional surgeries, providing targeted treatment, symptom relief, and improved quality of life for patients.

Country Insights

The Asia Pacific embolization devices market includes key countries such as China, Japan, India, Australia, South Korea, and others, with China holding the largest market share in 2024. China faces a significant burden of peripheral artery disease (PAD), with a reported 40% increase in cases from 2000 to 2020. The country has the highest number of type 2 diabetes patients in the region, which is a major risk factor for PAD. The prevalence of PAD among diabetic patients in China ranges from 6% to 10%.

Technological advancements are crucial for market growth, with companies like MicroPort leading the development of embolization devices tailored to local needs. Strategic activities, such as acquisitions and product innovations, are common among market players. For example, Grand Pharmaceutical acquired Shenming Medical Technology to enhance its tumor intervention product pipeline, while Zylox-Tonbridge received approval for its embolization system in early 2024.

Company Profiles

Key players in the embolization devices market include Medtronic, Cook Medical, Stryker, Boston Scientific, Terumo, Johnson & Johnson, Abbott Laboratories, and others. These companies are focusing on expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to consumers.

Product Code: BMIRE00032148

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Asia Pacific Embolization Devices Market - Key Market Dynamics

4.1 Asia Pacific Embolization Devices Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Clinical Conditions
- 4.2.2 Burgeoning Demand for Minimally Invasive Techniques
4.3 Market Restraints
- 4.3.1 Complications Arising During or After Embolization
4.4 Market Opportunities
- 4.4.1 New Product Developments and Marketing Approvals
4.5 Future Trends
- 4.5.1 Transforming Embolization Through Clinical Innovation
4.6 Impact of Drivers and Restraints:

5. Embolization Devices Market - Asia Pacific Analysis

5.1 Asia Pacific Embolization Devices Market Revenue (US$ Million), 2021-2031
5.2 Asia Pacific Embolization Devices Market Forecast Analysis

6. Asia Pacific Embolization Devices Market Analysis - by Product Type

6.1 Embolization Coils
- 6.1.1 Overview
- 6.1.2 Embolization Coils: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Plugs
- 6.2.1 Overview
- 6.2.2 Plugs: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.3 Beads
- 6.3.1 Overview
- 6.3.2 Beads: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.4 Glues
- 6.4.1 Overview
- 6.4.2 Glues: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Embolization Devices Market Analysis - by Application

7.1 Neurology
- 7.1.1 Overview
- 7.1.2 Neurology: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Peripheral Vascular Disease
- 7.2.1 Overview
- 7.2.2 Peripheral Vascular Disease: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Oncology
- 7.3.1 Overview
- 7.3.2 Oncology: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Urology
- 7.4.1 Overview
- 7.4.2 Urology: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Embolization Devices Market Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Ambulatory Centers
- 8.2.1 Overview
- 8.2.2 Ambulatory Centers: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Embolization Devices Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Embolization Devices Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 Asia Pacific Embolization Devices Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 China: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.2.1 China: Asia Pacific Embolization Devices Market Share - by Product Type
    - 9.1.1.2.2 China: Asia Pacific Embolization Devices Market Share - by Embolization Coils
    - 9.1.1.2.3 China: Asia Pacific Embolization Devices Market Share - by Application
    - 9.1.1.2.4 China: Asia Pacific Embolization Devices Market Share - by End User
  - 9.1.1.3 Japan: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.3.1 Japan: Asia Pacific Embolization Devices Market Share - by Product Type
    - 9.1.1.3.2 Japan: Asia Pacific Embolization Devices Market Share - by Embolization Coils
    - 9.1.1.3.3 Japan: Asia Pacific Embolization Devices Market Share - by Application
    - 9.1.1.3.4 Japan: Asia Pacific Embolization Devices Market Share - by End User
  - 9.1.1.4 India: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.4.1 India: Asia Pacific Embolization Devices Market Share - by Product Type
    - 9.1.1.4.2 India: Asia Pacific Embolization Devices Market Share - by Embolization Coils
    - 9.1.1.4.3 India: Asia Pacific Embolization Devices Market Share - by Application
    - 9.1.1.4.4 India: Asia Pacific Embolization Devices Market Share - by End User
  - 9.1.1.5 Australia: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.5.1 Australia: Asia Pacific Embolization Devices Market Share - by Product Type
    - 9.1.1.5.2 Australia: Asia Pacific Embolization Devices Market Share - by Embolization Coils
    - 9.1.1.5.3 Australia: Asia Pacific Embolization Devices Market Share - by Application
    - 9.1.1.5.4 Australia: Asia Pacific Embolization Devices Market Share - by End User
  - 9.1.1.6 South Korea: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.6.1 South Korea: Asia Pacific Embolization Devices Market Share - by Product Type
    - 9.1.1.6.2 South Korea: Asia Pacific Embolization Devices Market Share - by Embolization Coils
    - 9.1.1.6.3 South Korea: Asia Pacific Embolization Devices Market Share - by Application
    - 9.1.1.6.4 South Korea: Asia Pacific Embolization Devices Market Share - by End User
  - 9.1.1.7 Rest of APAC: Asia Pacific Embolization Devices Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.1.7.1 Rest of APAC: Asia Pacific Embolization Devices Market Share - by Product Type
    - 9.1.1.7.2 Rest of APAC: Asia Pacific Embolization Devices Market Share - by Embolization Coils
    - 9.1.1.7.3 Rest of APAC: Asia Pacific Embolization Devices Market Share - by Application
    - 9.1.1.7.4 Rest of APAC: Asia Pacific Embolization Devices Market Share - by End User

10. Competitive Landscape

10.1 Heat Map Analysis by Key Players
10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview
11.2 Expansion
11.3 New Product Development and Approval
11.4 Merger and Acquisition
11.5 Partnerships and Collaboration

12. Company Profiles

12.1 Medtronic Plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Cook Medical Holdings LLC
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Stryker Corp
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Boston Scientific Corp
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Terumo Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Johnson & Johnson
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Abbott Laboratories
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 NeuroSafe Medical Co. Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Wallaby Medical
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Sirtex Medical Ltd
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 GEM srl
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments
12.12 Penumbra Inc.
- 12.12.1 Key Facts
- 12.12.2 Business Description
- 12.12.3 Products and Services
- 12.12.4 Financial Overview
- 12.12.5 SWOT Analysis
- 12.12.6 Key Developments
12.13 Balt
- 12.13.1 Key Facts
- 12.13.2 Business Description
- 12.13.3 Products and Services
- 12.13.4 Financial Overview
- 12.13.5 SWOT Analysis
- 12.13.6 Key Developments
12.14 Lepu Medical Technology Beijing Co Ltd
- 12.14.1 Key Facts
- 12.14.2 Business Description
- 12.14.3 Products and Services
- 12.14.4 Financial Overview
- 12.14.5 SWOT Analysis
- 12.14.6 Key Developments
12.15 INVAMED
- 12.15.1 Key Facts
- 12.15.2 Business Description
- 12.15.3 Products and Services
- 12.15.4 Financial Overview
- 12.15.5 SWOT Analysis
- 12.15.6 Key Developments
12.16 Meril Life Sciences Pvt Ltd
- 12.16.1 Key Facts
- 12.16.2 Business Description
- 12.16.3 Products and Services
- 12.16.4 Financial Overview
- 12.16.5 SWOT Analysis
- 12.16.6 Key Developments
12.17 Merit Medical Systems Inc
- 12.17.1 Key Facts
- 12.17.2 Business Description
- 12.17.3 Products and Services
- 12.17.4 Financial Overview
- 12.17.5 SWOT Analysis
- 12.17.6 Key Developments
12.18 Lifetech Scientific Corp
- 12.18.1 Key Facts
- 12.18.2 Business Description
- 12.18.3 Products and Services
- 12.18.4 Financial Overview
- 12.18.5 SWOT Analysis
- 12.18.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms